cliffordfosterr
125 posts
Sep 16, 2024
2:56 AM
|
Which clinical trials have shown significant benefits of Sildigra 250 Mg for pulmonary arterial hypertension?
Sildigra 250 mg, which contains sildenafil citrate, is used for the treatment of pulmonary arterial hypertension (PAH). The clinical trials evaluating sildenafil for PAH have primarily focused on the standard dosage of 20 mg or 40 mg, rather than the 250 mg dose.
The most notable trials for sildenafil in PAH include:
The STARTS-1 Trial (Sildenafil Trial to Assess Routine Therapy in PAH Study 1): This study demonstrated that sildenafil improved exercise capacity and hemodynamics in PAH patients. However, it used doses of 20 mg and 40 mg rather than 250 mg.
The STARTS-2 Trial (Sildenafil Trial to Assess Routine Therapy in PAH Study 2): This follow-up study confirmed the long-term benefits of sildenafil in PAH patients who had previously participated in the STARTS-1 trial, again focusing on lower doses.
The SUPER Study (Sildenafil Use in Pulmonary Arterial Hypertension): This study showed that sildenafil improved exercise capacity and quality of life in PAH patients. The trial used doses of 20 mg and 40 mg.
The STRIDE-1 and STRIDE-2 Studies (Sildenafil Trial to Reduce Disease Progression and Exertional dyspnea): Sildigra 250 studies provided evidence of the efficacy of sildenafil in PAH, showing improvements in exercise capacity and hemodynamic parameters.
While these studies established the efficacy of sildenafil in treating PAH, there is limited data on the use of a 250 mg dose specifically. Typically, higher doses like 250 mg are not commonly used due to the risk of side effects and are not generally recommended based on current evidence.
For the most accurate and up-to-date information, checking the latest literature and clinical guidelines or consulting a healthcare provider is advisable.
|
